Berend J. van Welzen

Changes in Inflammatory and Atherogenesis Biomarkers With the 2-Drug Regimen Dolutegravir Plus Lamivudine in Antiretroviral Therapy–Experienced, Virologically Suppressed People With HIV-1: A Systematic Literature Review

Josep M. Llibre, Pedro Cahn, Janet Lo et al. · Open Forum Infectious Diseases · 2022 · 46 citations · Full text

Virological Failure After Switch to Long-Acting Cabotegravir and Rilpivirine Injectable Therapy: An In-depth Analysis

Berend J. van Welzen, S.F.L. van Lelyveld, G. ter Beest et al. · Clinical Infectious Diseases · 2024 · 46 citations · Full text

Twelve‐month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in people with <scp>HIV</scp>: Real‐world insights from <scp>BICSTaR</scp> cohorts

Jason Brunetta, Alexy Inciarte, Itzchak Levy et al. · HIV Medicine · 2023 · 39 citations · Full text

National medical specialty guidelines of HIV indicator conditions in Europe lack adequate HIV testing recommendations: a systematic guideline review

Carlijn Jordans, Marta Vasylyev, Caroline Rae et al. · Eurosurveillance · 2022 · 27 citations · Full text

Hiv Ic, Backgroundadequate Identification, Hiv Ic Guidelines +25

Decreased All-Cause and Liver-Related Mortality Risk in HIV/Hepatitis B Virus Coinfection Coinciding With the Introduction of Tenofovir-Containing Combination Antiretroviral Therapy

Berend J. van Welzen, Colette Smit, Anders Boyd et al. · Open Forum Infectious Diseases · 2020 · 22 citations · Full text